» Articles » PMID: 6302586

[3H] Quinuclidinyl Benzylate and [3H] GABA Receptor Binding in Rat Substantia Nigra After 6-hydroxy-dopamine Lesions

Overview
Journal Neurosci Lett
Specialty Neurology
Date 1980 May 1
PMID 6302586
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

6-Hydroxydopamine lesions of the nigrostriatal DA pathway resulted in a 30% reduction (P less than 0.01) of nigral [3H] quinuclidinyl benzylate (QNB) binding at 3 weeks after lesion and this reduction in binding was characterised by a loss of [3H] QNB binding sites with no change in affinity. The binding of [3H] GABA to Triton-treated membranes was 12% lower (non-significant) in the nigrae of the lesioned than of the non-lesioned hemisphere, but was not characterised further. The results suggest the location of muscarinic ACh receptors on the cell bodies or dendrites of nigral DA neurons.

Citing Articles

Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's disease.

Xiang Z, Thompson A, Jones C, Lindsley C, Conn P J Pharmacol Exp Ther. 2011; 340(3):595-603.

PMID: 22135383 PMC: 3286317. DOI: 10.1124/jpet.111.187856.


A comparison of behaviour following stimulation of the anterior substantia nigra by direct cholinergic agonists and anticholinesterases.

Parker G, Inglis W, Winn P Psychopharmacology (Berl). 1993; 112(2-3):242-8.

PMID: 7871026 DOI: 10.1007/BF02244917.


Role of muscarinic cholinergic mechanisms in the substantia nigra pars reticulata in mediating muscular rigidity in rats.

Turski L, Havemann U, Kuschinsky K Naunyn Schmiedebergs Arch Pharmacol. 1984; 327(1):14-7.

PMID: 6493347 DOI: 10.1007/BF00504985.


Effects of 3-quinuclidinyl benzilate on fixed-ratio responding and open field behavior in the rat.

Liu W, Hu N, Chien T, Beaton J Psychopharmacology (Berl). 1983; 80(1):10-3.

PMID: 6408662 DOI: 10.1007/BF00427485.


Electrophysiological actions of nicotine on substantia nigra single units.

CLARKE P, Hommer D, Pert A, Skirboll L Br J Pharmacol. 1985; 85(4):827-35.

PMID: 4041681 PMC: 1916681. DOI: 10.1111/j.1476-5381.1985.tb11081.x.